Thomas J. Herzog

Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial

B.J. Monk, Maria Pilar Barretina-Ginesta, Bhavana Pothuri et al. · Annals of Oncology · 2024 · 150 citations · Full text

Medicine, Oncology, Pharmacology +17

Topotecan in Platinum- and Paclitaxel-Resistant Ovarian Cancer

Elizabeth M. Swisher, David G. Mutch, Janet S. Rader et al. · Gynecologic Oncology · 1997 · 146 citations

Medicine, Oncology, Pharmacology +12

Clinical significance of microsatellite instability in endometrial carcinoma

Jack Basil, Paul J. Goodfellow, Janet S. Rader et al. · Cancer · 2000 · 124 citations · Full text

Life Sciences, Genetics, Oncology +16

Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial

Rodney P. Rocconi, Elizabeth A. Grosen, Sharad Ghamande et al. · The Lancet Oncology · 2020 · 115 citations

Medicine, Immunology, Oncology +12

ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA–MONO) and rucaparib in combination with nivolumab (ATHENA–COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer

Bradley J. Monk, Robert L. Coleman, Keiichi Fujiwara et al. · International Journal of Gynecological Cancer · 2021 · 91 citations · Full text

Medicine, Oncology, Pharmacology +17